TY - JOUR T1 - Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU) JF - medRxiv DO - 10.1101/2022.01.30.22269685 SP - 2022.01.30.22269685 AU - Raja Dhar AU - John Kirkpatrick AU - Laura Gilbert AU - Arjun Khanna AU - Mahavir Madhavdas Modi AU - Rakesh K. Chawla AU - Sonia Dalal AU - Venkata Nagarjuna Maturu AU - Marcel Stern AU - Oliver Keppler AU - Ratko Djukanović AU - Stephan Gadola Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/22/2022.01.30.22269685.abstract N2 - Background After admission to hospital, COVID-19 progresses in a substantial proportion of patients to critical disease that requires intensive care unit (ICU) admission.Methods In a pragmatic, non-blinded trial, 387 patients aged 40-90 years were randomised to receive treatment with SoC plus doxycycline (n=192) or SoC only (n=195). The primary outcome was the need for ICU admission as judged by the attending physicians. Three types of analyses were carried out for the primary outcome: “Intention to treat” (ITT) based on randomisation; “Per protocol” (PP), excluding patients not treated according to randomisation; and “As treated” (AT), based on actual treatment received. The trial was undertaken in six hospitals in India with high-quality ICU facilities. An online application serving as the electronic case report form was developed to enable screening, randomisation and collection of outcomes data.Results Adherence to treatment per protocol was 95.1%. Among all 387 participants, 77 (19.9%) developed critical disease needing ICU admission. In all three primary outcome analyses, doxycycline was associated with a relative risk reduction (RRR) and absolute risk reduction (ARR): ITT 31.6% RRR, 7.4% ARR (P=0.063); PP 40.7% RRR, 9.6% ARR (P=0.017); AT 43.2% RRR, 10.8% ARR (P=0.007), with numbers needed to treat (NTT) of 13.4 (ITT), 10.4 (PP), and 9.3 (AT), respectively. Doxycycline was well tolerated with not a single patient stopping treatment due to adverse events.Conclusions In hospitalized COVID-19 patients, doxycycline, a safe, inexpensive, and widely available antibiotic with anti-inflammatory properties, reduces the need for ICU admission when added to SoC.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI202105033867Clinical Protocols https://cmri.ckbirlahospitals.com/Study_Protocol_DOXPREVENT.pdf Funding StatementThis study received an unrestricted grant (Rs 500,000.00, corresponding to approx. USD 6730.00) from the pharmaceutical company, Cipla (Mumbai, India)(Study code IIS/11/20) to support a part-time salary of a study coordinator who assisted the Chief Investigator. Cipla had no role in the trial design, data collection, data analysis, data interpretation, or writing of the manuscript. No external funding was received for any other work related to this trial.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Committees of (1) The Calcutta Medical Research Institute, Kolkata, and (2) The Poona Medical Research Foundation, Pune, gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at GitHub the following data repository: https://github.com/PuzzledFace/DoxyICU_Results https://github.com/PuzzledFace/DoxyICU_Results ER -